Enhanced Delivery Oligonucleotide (EDO) – A Novel Peptide Delivery Platform for Superior Oligonucleotide Delivery
Time: 11:30 am
day: Conference Day Two
Details:
- EDOs are designed to enhance delivery of oligonucleotide therapeutics to muscle and other target tissues
- EDOs show higher uptake to muscle nuclei and corresponds with increased pharmacological activity in multiple preclinical models
- EDO platform has enabled initiation of 2 clinical programs, including a Phase 2 (CONNECT1-EDO51) study to investigate the effects of PGN-EDO51 in people with DMD amendable to exon 51 skipping and a Phase 1 (FREEDOM-DM1) study to investigate the effects of PGN-EDODM1 in people with DM1
NEW DATA
